US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2025-10-24 16:12:08 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1200/jco-25-00167
文献链接: https://ascopubs.org/doi/10.1200/JCO-25-00167
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Jennifer J. Gao; Tatiana M. Prowell; Haley Gittleman; Joyce Cheng; Mallorie Fiero; Ilynn Bulatao; George Ching-Jey Chang; Tiffany K. Ricks; Francis Green; Huali Wu; Jingyu Yu; Manuela Grimstein; Yuching Yang; Hong Zhao; Qi Liu; Rohit Kolhatkar; Tingting Gao; Chi-Ming Tu; Sherry Hou; Susan Redwood; Barbara Fuller; LaShawn Griffiths; Mispa Ajua-Alemanji; Courtney Leach; Stacie Woods; Oladimeji Akinboro; Preeti Narayan; Mirat Shah; Christy Osgood; Ramesh Raghavachari; Atiqur Rahman; Shenghui Tang; Vishal Bhatnagar; Nicole Gormley; Tamy Kim; William F. Pierce; Richard Pazdur; Paul G. Kluetz; Laleh Amiri-Kordestani
